Latest news and press releases about Minerva Neurosciences, Inc. (NERV): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system.
Price
| Price | $3.48 |
| Market Cap | $162M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -0.78 |
| EV / EBITDA | -0.46 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 250.02% |
| Return on Invested Capital | -38.56% |
| Return on Assets | -414.72% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLGN · CVKD · ENLV · KLTO · NRSN · NRXS · RLYB
Explore sector: Healthcare · Biotechnology
More sections of NERV: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks